1. Enbrel [Prescribing information]. Thousand Oaks, CA: Immunex Corporation; November 2016.
2. Cosentyx [Prescribing information]. East Hanover, NJ: Novartis; January 2016.
3. Humira [Prescribing information]. North Chicago, IL: AbbVie Inc; June 2016.
4. Stelara [Prescribing information] Horsham, PA: Janssen Biotech Inc; March 2014.
5. Cimzia [Prescribing Information] Smyrna, GA: UCB, Inc; April 2016.
6. Simponi [Prescribing information]. Horsham, PA: Janssen Biotech Inc; January 2016.
7. Simponi Aria [Prescribing information]. Horsham, PA: Janssen Biotech Inc; April 2016.
8. Kineret [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ). May 2016.
9. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis and Rheumatism September 2010;62(9):2569-2581.
10. Zochling J, van der Heijde D, Burgos-Vargas, R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442-452.
11. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:316-320.
12. Boulos P, Dougados M, MacLeod SM, et al. Pharmacological Treatment of Ankylosing Spondylitis. Drugs. 2005; 65: 2111-2127.
13. Colombel JF, Sandborn WJ, Rutgeerts P, et.al. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn`s Disease: The CHARM Trial. Gastroenterology 2007;132:52-65.
14. Lichtenstein G, Hanauer S, Sandborn W, et al. Management of Crohn`s Disease in Adults. Am J Gastroenterol 2009;104:465-483.
15. Menter A, Gottlieb A, Feldman SR, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850.
16. Menter A, Gottlieb A, Feldman, SR, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol May 2008; 58(5): 826-50.
17. Menter A, Korman, NJ, Elmets CA, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643-659.
18. Menter A, Korman NF, Elmets cA, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 10.1016/j.jaad.2009.03.027
19. Braun J, van den Berg R, Baraliako X, et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896-904.
20. Enbrel, Cimzia, Humira, Kineret, Simponi, Stelara. American Hospital Formulary Service Drug Information. Available at: http://www.medicinescomplete.com/mc/ahfs/current/. Accessed June 8, 2015.
21. DRUGDEXR System [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed July 2016.
22. Ward M, Deodhar A, Akl E, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Available at http://www.rheumatology.org. Accessed February 16, 2016.
23. Orencia [Prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2016.
24. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid Arhritis Classification Criteria. Arthritis and Rheumatism September 2010;62(9):2569-2581.
25. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
26. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 15;353:1114-23.
27. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(8):2263-71.
28. Maini R, St Clair EW, Breedveld F, Furst D, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 ;354:1932-9.
29. Orencia. American Hospital Formulary Service Drug Information. Available at: http://www.medicinescomplete.com/mc/ahfs/current/. Accessed July 2017.
30. Hyrick KL et al. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 2008; 47:10001005
31. Rendas-Baum R et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-a inhibitors. Arthritis Research & Therapy 2011 13:R25.
32. Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007 Jul;66(7):893-9. Epub 2007 Apr 5.
33. J. A. Karlsson, L. E. Kristensen, M. C. Kapetanovic, A., et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008;47:507513.
34. Orencia. In: DRUGDEX. System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com/. Accessed July 2016.
35. Actemra [Prescribing information]. South San Francisco, CA: Genentech, Inc; November 2014.
36. Singh JA, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research. May 2012;64(5):625-39.
37. DRUGDEX. Micromedex online database. Truven Health Analytics. Accessed July 2017.
38. Entyvio [Prescribing Information] Deerfield, IL: Takeda Pharmaceuticals America, Inc.; May 2014.
39. Micromedex. Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Healthcare. Updated periodically. Accessed January 28, 2016.
40. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
41. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for crohn`s disease. N Engl J Med 2013;369:711-721.
42. Clinical Pharmacology Web site. Available at: http://cpip.gsm.com/. Accessed January 28, 2016.
43. Pharmacist`s Letter [Internet database]. Stockton, CA: Therapeutic Research Center. Updated periodically. Accessed June 21, 2015.
44. WebMD. Inflammatory Bowel Disease Health Center. Available at: www.webmd.com/ibd-crohns-disease/default.htm . Accessed January 28, 2016.
45. Mayo Clinic. Inflammatory Bowel Disease. Available at: www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/basics/definition/CON-20034908 . Accessed January 28, 2016.
46. Lichtenstein GR, Abreumt, Cohen R, Tremaine W. American gastroenterological association institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:936-939.
47. Thomas A, Lodnia N. Advanced therapy for inflammatory bowel disease: A guide for the primary care physician. J Am Board Fam Med May-June Vol. 27 No. 3 411-420
48. Xeljanz/Xeljanz XR [Prescribing Information] New York, NY: Pfizer Labs. February 2016.
49. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis and Rheumatism. September 2010:62(9):2569-2581.
50. Singh J, Furst D, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research. May 2012;64(5):625-639.
51. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508-519.
52. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507.
53. Taltz [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; March 2016.
54. Inflectra [Prescribing information]. Lake Forest, IL: Hospira; April 2016.
55. Margesson LJ, Danby FW. Hidradenitis suppurativa (acne inversa): Treatment. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at: www.UpToDate.com. Accessed November 2016.